Trial Profile

A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Paclitaxel
Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms APPALACHES

Most Recent Events

23 Jan 2024 Planned primary completion date changed from 30 Sep 2027 to 30 Jun 2026.
16 Nov 2022 Planned End Date changed from 13 Sep 2032 to 30 Sep 2032.
16 Nov 2022 Planned primary completion date changed from 13 Sep 2027 to 30 Sep 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com